Table 3. Incidence of treatment-related adverse events.
| No. adverse events | Grade 1–2 | Grade 3* |
|---|---|---|
| Non-hematologic | ||
| Fatigue | 5 | 0 |
| Nausea | 3 | 0 |
| Proteinuria | 3 | 0 |
| Hematuria | 2 | 0 |
| Vomiting | 1 | 0 |
| Diarrhea | 1 | 0 |
| Infusion reaction | 1 | 0 |
| Pruritus | 1 | 0 |
| Myalgia | 1 | 0 |
| Cystitis | 1 | 0 |
| Cough | 1 | 0 |
| Hypertension | 1 | 0 |
| Alk Phos elevation | 1 | 0 |
| AST elevation | 1 | 0 |
| Cardiac chest pain | 0 | 1 |
| Hematologic | ||
| Anemia | 3 | 0 |
| Leukopenia | 2 | 0 |
| Neutropenia | 2 | 0 |
| Lymphopenia | 1 | 0 |
| Thrombocytopenia | 1 | 0 |
*, no grade 4 or 5 toxicities were observed. Alk Phos, alkaline phosphatase; AST, aspartate aminotransferase.